Results from the study were published in the academic journal Plos One this month, the company said.
”Increasing healthcare costs and a growing number of chronically ill patients are driving the need for more affordable and innovative options, like remote monitoring that may support better delivery of home healthcare. Baxter conducted this study to better understand the perceived multi-faceted value of remote monitoring, and the continued need for supportive funding and policies that may enable more patients to have access to the new technology,” Baxter renal prez Giuseppe Accogli said in a press release.
The Amia device, which uses Deerfield Park, Ill.-based Baxter’s ShareSource web-based remote connection, is designed for home use by patients with end-stage renal disease. Baxter claimed Amia as the sole U.S.-cleared device with voice guidance, touchscreen controls and ShareSource 2-way connectivity.
The study set out to observe funding approaches and policies supporting remote monitoring for chronic diseases, and included a study which indicated that healthcare payers place remote monitoring as a moderate to high priority for treating chronic diseases.
The most common factors contributing to high ratings for remote monitoring include living in rural areas away from doctors and hospitals, recent discharges from the hospital and rare, more serious or multiple disease patients.
Results indicated that despite support for remote monitoring being high, implementation of monitoring was “generally inconsistent.”
Last October, Baxter won 510(k) clearance from the FDA for its Amia automated peritoneal dialysis system, and launched the device late last year.
The post Baxter touts remote monitoring study for Amia dialysis device appeared first on MassDevice.
from MassDevice http://ift.tt/295LjtD
Cap comentari:
Publica un comentari a l'entrada